α-Glycosidase-IN-1

α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Carbonic Anhydrase

Research Areas >> Metabolic Disease

Research Areas >> Neurological Disease

Signaling Pathways >> Neuronal Signaling >> AChE

IC50: 44.72 ± 0.9964 nM (α-GLY), 100.04 ± 0.9688 nM (hCA II), 104.87 ± 0.9920 nM (hCA I), 654.87 ± 0.9383 nM (AChE); KI: 41.74 ± 8.08 nM (α-GLY), 114.78 ± 20.33 nM (hCA I), 114.78 ± 9.54 nM (hCA II), 597.33 ± 100.56 nM (AChE)[1]

[1]. Lolak N, et al. Synthesis, characterization, inhibition effects, and molecular docking studies as acetylcholinesterase, α-glycosidase, and carbonic anhydrase inhibitors of novel benzenesulfonamides incorporating 1,3,5-triazine structural motifs. Bioorg Chem. 2020 Jul;100:103897.